Related Experiment Video
Updated: Aug 9, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic virus therapy for malignant gliomas: entering the new era
Hirotaka Fudaba1,2, Hiroaki Wakimoto1
1Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Introduction:
To overcome the challenge of treating malignant brain tumors, oncolytic viruses (OVs) represent an innovative therapeutic approach, featuring unique mechanisms of action. The recent conditional approval of the oncolytic herpes simplex virus G47Δ as a therapeutic for malignant brain tumors marked a significant milestone in the long history of OV development in neuro-oncology.
Areas Covered:
This review summarizes the results of recently completed and active clinical studies that investigate the safety and efficacy of different OV types in patients with malignant gliomas. The changing landscape of the OV trial design includes expansion of subjects to newly diagnosed tumors and pediatric populations. A variety of delivery methods and new routes of administration are vigorously tested to optimize tumor infection and overall efficacy. New therapeutic strategies such as combination with immunotherapies are proposed that take advantage of the characteristics of OV therapy as an immunotherapy. Preclinical studies of OV have been active and aim to translate new OV strategies to the clinic.
Expert Opinion:
For the next decade, clinical trials and preclinical and translational research will continue to drive the development of innovative OV treatments for malignant gliomas and benefit patients and define new OV biomarkers.
Insights
Oncolytic viruses (OVs) offer a promising new treatment for malignant brain tumors, with ongoing clinical trials exploring their safety and efficacy. Future research will focus on optimizing OV delivery and combining them with immunotherapies for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Virology
- Immunotherapy
Background:
- Malignant brain tumors present significant treatment challenges.
- Oncolytic viruses (OVs) are an emerging therapeutic strategy with unique mechanisms.
- The conditional approval of oncolytic herpes simplex virus G47Δ marks a milestone.
Approach:
- This review synthesizes data from completed and active clinical studies on OVs for malignant gliomas.
- It examines diverse OV types, delivery methods, and routes of administration.
- The review also covers combination strategies, particularly with immunotherapies.
Key Points:
- Clinical trial designs are evolving to include newly diagnosed tumors and pediatric patients.
- Optimizing tumor infection and efficacy through novel delivery methods is a key focus.
- Combining OV therapy with immunotherapies leverages OV's inherent immune-stimulating properties.
Conclusions:
- Continued clinical trials and preclinical research are essential for advancing OV treatments for malignant gliomas.
- Future efforts will focus on developing innovative OV strategies and identifying relevant biomarkers.
- These advancements aim to improve patient benefit and treatment efficacy in neuro-oncology.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...